22 results about "Neuraminic acid" patented technology

The invention discloses recombinant escherichia coli with high yield of N-acetylneuraminic acid and application of the recombinant escherichia coli, and relates to the technical field of biological genetic engineering. The invention relates to a recombinant escherichia coli, which is characterized in that the escherichia coli is taken as a host, and free expression of an N-acetylmannosamine epimerase gene yihS from Streptomyces xiamenensis or an N-acetylmannosamine epimerase gene ce3 from Bacteroides polymorpha and an exogenous N-acetylneuraminic acid lyase gene nano A is carried out; and carrying out recombinant expression on N-acetyl hexosamine 1-kinase nahK, a UDP-N-acetyl glucosamine pyrophosphorylase gene glmU and a UDP-N-acetyl glucosamine-2-epimerase gene neuC in the other synthetic route of the ManNAc. According to the recombinant escherichia coli with high yield of N-acetylneuraminic acid, the yield of N-acetylneuraminic acid can reach 23.08 g / L under a shake flask fermentation condition; a two-stage batch feeding strategy is adopted, the yield of N-acetylneuraminic acid in a 5L fermentation tank reaches 71.25 g / L, the molar conversion rate of GlcNAc reaches up to 57.60%, and the method has the potential of industrial application.

The invention relates to an N-acetylneuraminic acid fermentation method capable of reducing fermentation byproducts, and belongs to the technical field of fermentation. Escherichia coli is used as a chassis strain for fermentation synthesis of N-acetylneuraminic acid, sodium hexametaphosphate is added in the fermentation process to reduce generation of byproducts in the synthesis process of N-acetylneuraminic acid, and fermentation conditions are further optimized to improve the synthesis yield of N-acetylneuraminic acid. According to the fermentation method, the N-acetylneuraminic acid can be efficiently synthesized, the yield of the N-acetylneuraminic acid is increased, meanwhile, by-products difficult to separate are reduced, and a technical basis is provided for subsequent fermentation amplification and industrial production of the N-acetylneuraminic acid.

This invention relates to the field of cosmetic technology, specifically disclosing a synergistic exfoliating composition and a method for preparing a controlled-release carrier containing the composition. The synergistic exfoliating composition is a compound of adenosine, N-acetylneuraminic acid, and lactobionic acid. This invention has the advantage of maintaining good exfoliating efficacy while reducing skin irritation.

The application relates to the technical field of medicines, in particular to application of N-acetylneuraminic acid in preparation of medicines for preventing and / or treating ulcerative colitis. The application finds that N-acetylneuraminic acid can effectively prevent or treat ulcerative colitis and promote tissue repair by regulating macrophage metabolism, inhibiting glycolysis pathways and M1 type polarization, and simultaneously repairing intestinal mucosal barrier, thereby providing a safe, simple and clear mechanism of action new treatment strategy for clinic.

The invention provides a preparation method of an antibody conjugate containing an sLeX tetrasaccharide structure, which comprises the following steps: S1, sequentially adding Endo S2 enzyme and alpha-L-fucosidase into a target antibody, and respectively analyzing glycosylation to avoid modification site conflict or carbohydrate chain structure interference; s2, adding the accurately represented antibody in the S1, B4GalT1 and UDP-Gal into a Tris-HCl system containing Mn < 2 + >, and incubating to obtain a reaction solution I; s3, the reaction liquid I, ST3Gal3, CMP-Neu5Ac and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is carried out; adding CMP-N-acyl neuraminic acid phosphodiesterase for reaction, and purifying Protein A to obtain a purified antibody I; s4, the purified antibody I, alpha1, 3 FucT-2HR, GDP-Fuc and Tris-HCl containing Mg < 2 + > are taken and mixed, and incubation is performed; and purifying Protein A to obtain a target product. According to the modified antibody obtained by the invention, while the targeting property is improved, the binding affinity of the antibody and a tumor cell surface antigen can be enhanced, so that the immune blocking activity of the antibody is further enhanced, and dual improvement of the targeting property and the activity is realized.

The present invention relates to a novel and efficient method for sialylation of a glycoside comprising mixing said glycoside with sialic acid, cytidine monophosphate, nucleoside triphosphate and one or more cell-free extracts of a microorganism, the present invention relates to a microorganism comprising one or more endogenous polypeptides having inorganic diphosphatase activity and one or more endogenous polypeptides having phosphotransferase activity, and wherein the one or more cell-free extracts comprise: at least one polypeptide having cytidine monophosphate kinase activity, at least one polypeptide having N-acyl neuraminic acid cytidyltransferase activity, and at least one polypeptide having sialyltransferase activity, thereby sialylating the glycoside.

The invention discloses a method for quantitatively analyzing the content of alpha2-3 acetylneuraminic acid in glycoprotein, which comprises the following steps: firstly, treating a sample containing glycoprotein by using streptococcus pneumoniae acetylneuraminidase, and continuously treating the sample containing glycoprotein by using clostridium perfringens acetylneuraminidase in the same solution; centrifugally separating and taking a separating solution containing two acetylneuraminic acid products outside the centrifugal tube; and detecting and collecting two hydrolysates 2, 7-dehydrated acetylneuraminic acid and the signal intensity of acetylneuraminic acid in a negative ion mode, and calculating the percentage content of alpha2-3 linked acetylneuraminic acid by using a formula. According to the method, the sensitivity of quantitative analysis of alpha2-3 acetylneuraminic acid can be improved, and the time consumption of detection and analysis is reduced.

Disclosed are methods for the fermentative production of a sialylated saccharide and genetically engineered microbial cells for use in said method, wherein the genetically engineered microbial cells comprise (i) a sialic acid biosynthesis pathway comprising a glucosamine-6-phosphate N-acetyltransferase, (ii) a cytidine 5′-monophospho-(CMP)-N-acetylneuraminic acid synthetase; and (iii) a sialyitransferase, for producing sialylated saccharides, as well as the use of said sialylated oligosaccharides for providing nutritional compositions.

The invention relates to an elsholtzia and ginseng composite peptide special diet for improving cardiovascular and cerebrovascular diseases and microcirculation disturbance and a preparation method thereof. The special diet comprises the following components: 5-15% of small molecule peptide; 18-65% of a plant extract; 0.1 to 3 percent of gamma-aminobutyric acid; 0.01 to 1 percent of N-acetylneuraminic acid; 0.005% to 0.1% of thiamine; 0.001 to 0.05 percent of riboflavin; and the balance of auxiliary materials. Wherein the plant extract comprises at least one of elsholtzia, rhizoma zingiberis and ginseng. According to the scheme provided by the invention, the elasticity and permeability of blood capillaries can be improved, microcirculation can be improved, blood fat can be reduced, and cardiovascular and cerebrovascular diseases can be effectively prevented and relieved.

The invention relates to the technical field of biological medicines, in particular to application of N-acetylneuraminic acid in preparation of a medicine for treating methamphetamine addiction. The key effect of N-acetylneuraminic acid (Neu5Ac) in methamphetamine addiction treatment is found for the first time, the CPP score of a methamphetamine addiction mouse can be obviously reduced, it is proved that the N-acetylneuraminic acid (Neu5Ac) has a good treatment effect on methamphetamine addiction, and Neu5Ac can be subjected to endogenous synthesis and has the advantages of being good in biocompatibility and small in toxic and side effect.

The invention provides an anti-aging composition containing collagen and application of the anti-aging composition. The anti-aging composition containing the collagen is prepared from the following components in percentage by mass: 2 to 5 percent of protein substances, 0.05 to 0.2 percent of aldehyde compounds, 4 to 6 percent of N-acetylneuraminic acid, 0.5 to 2 percent of retinol substances, 1 to 3 percent of phosphatidylcholine and the balance of a basic matrix. The collagen-containing anti-aging composition prepared by the invention has the advantages that the surface wrinkle area reduction amount is obviously reduced, the wrinkle fading period is obviously shortened, the skin resilience is good, the DPPH free radical scavenging rate is higher, the skin surface wrinkles can be obviously reduced after long-term use, the skin resilience is improved, the wrinkle fading period is short, and the anti-aging effect is good. The antioxidant effect and the anti-aging effect are better.

This invention relates to the field of cosmetic technology, disclosing the application of N-acetylneuraminic acid in synergistically enhancing the skincare effects of acetyl hexapeptide-8. By combining N-acetylneuraminic acid and acetyl hexapeptide-8 in the mass ratios provided in this application, a synergistic effect on the anti-aging effects of acetyl hexapeptide-8 can be achieved, increasing the content of collagen and elastin in the skin. However, when the ratio of N-acetylneuraminic acid to acetyl hexapeptide-8 is adjusted outside the range provided in this application, the synergistic effect disappears. Therefore, by using N-acetylneuraminic acid and acetyl tetrapeptide-2 synergistically in cosmetics and / or skincare products according to the compounding ratios provided in this application, significant anti-aging effects can be achieved at lower application amounts, improving skin firmness and elasticity, and reducing the formation of wrinkles.

The invention provides a UDP-N-acetylmannosamine epimerase mutant as well as a recombinant strain and application of the UDP-N-acetylmannosamine epimerase mutant. Compared with a wild type, the UDP-N-acetylmannosamine epimerase mutant disclosed by the invention has higher enzyme activity, can be used for efficiently preparing N-acetylneuraminic acid, and has the potential of industrial application.

The invention discloses a composition for repairing neural pathways and delaying senescence of cerebral nerve cells and a preparation method of the composition, and belongs to the technical field of biological medicines and functional foods. The composition is prepared from malus hupehensis (tea crabapple) leaves, phosphorylserine, N-acetylneuraminic acid, maltodextrin, mulberry leaf extract, L-alpha-choline alfoscerate, epigallocatechin gallate, bamboo leaf flavone, micrococcus, vitamin B1 and vitamin B2, and all the components are scientifically matched to achieve synergistic interaction. The preparation method comprises the steps of raw material pretreatment, mixing, crushing and sieving, sterilization and packaging, and finally the powder dosage form is prepared. The composition can regulate and control the nerve protection process in a multi-target mode, effectively repair damaged nerve pathways and delay cerebral nerve cell senescence, the raw materials are natural and safe, taking is convenient, the absorption efficiency is high, the preparation technology is simple and stable and suitable for industrial production, and a solution is provided for prevention and auxiliary improvement of neurodegenerative diseases.

The present invention relates to a method for producing N-acetylneuraminic acid, comprising the steps of: infecting eukaryotic cells with a baculovirus bearing an exogenous gene encoding an N-acetylglucosamine 2-epimerase and an N-acetylneuraminic acid aldolase, the N-acetylglucosamine 2-epimerase and the N-acetylneuraminic acid aldolase can be expressed by the aid of the N-acetylglucosamine 2-epimerase; and culturing the obtained eukaryotic cell infected by the baculovirus in the presence of N-acetyl glucosamine and pyruvic acid.

The application provides a blue and indigo fruit oral liquid with sleep promotion and fatigue relief effects and a production process thereof, and relates to the field of health-care drinks. The indigo fruit pulp amino acid composite drink is mainly prepared by mixing and freeze-thawing a blue and indigo fruit composite extract, a spina date seed extract liquid, gamma-aminobutyric acid, N-acetylneuraminic acid, vitamin C, nicotinamide, citric acid, sucralose and xylitol. The blue and indigo fruit composite extract is obtained by mixing after being treated by means of pressing separation, fruit juice enzymolysis, water extraction of fruit residue and fermentation of the residue after water extraction. The application overcomes the defects of the prior art, improves the utilization rate of the nutrients of the blue and indigo fruit, ensures the performance stability of the drink during long-time storage, and achieves a good anti-fatigue health-care effect.

Use of an N-acetylneuraminic acid substance in the preparation of a food product for promoting the regulation of gut microbiota of a mother and offspring thereof via ingestion by the mother. The N-acetylneuraminic acid substance is an N-acetylneuraminic acid anhydrate, an N-acetylneuraminic acid hydrate or an N-acetylneuraminic acid salt. The mother is in a gestational period and / or lactation period, and the offspring is in a fetal stage, infant stage and / or toddler stage. The mother starting to ingest the N-acetylneuraminic acid substance in the gestational period can promote the increase of beneficial bacteria in the gut in the gestational and lactation periods, and can also increase the content of probiotics in the offspring gut, inhibit the proliferation of opportunistic pathogens in the offspring gut and reduce the relative abundance thereof, thereby further contributing to maintaining the health of the nervous system by means of the action of the gut-brain axis.

This application relates to the field of biomedical technology, and in particular to the application of N-acetylneuraminic acid in the preparation of drugs for treating methamphetamine addiction. This application is the first to discover the key role of N-acetylneuraminic acid (Neu5Ac) in the treatment of methamphetamine addiction, which can significantly reduce the CPP score in methamphetamine-addicted mice, demonstrating a good therapeutic effect on methamphetamine addiction. Furthermore, Neu5Ac can be synthesized endogenously, exhibiting advantages such as good biocompatibility and low toxicity.

The application discloses a set of applications of glycosylation related gene markers in liver cancer detection and belongs to the technical field of biotechnology.The glycosylation related gene markers are composed of five types of 10 genes, namely, neuraminidase 1 (NEU1), N-acetylneuraminic acid synthase (NANS), cytidine monophosphate N-acetylneuraminic acid hydroxylase (CMAH), solute carrier family 35 member A1 (SLC35A1) and glycosyltransferase (B3GALT4, B3GALNT2, ALG2, MGAT2, FUT8 and ST3GAL2). The application first uses the markers as liver cancer diagnostic markers for liver cancer detection, and the average AUC of liver cancer can reach 82.14% through combined diagnosis of the multiple indexes of the set of genes.Compared with AFP which is widely used at present, the sensitivity and specificity of diagnosis can be greatly improved, and the technology still takes blood samples as the main detection target, and does not cause secondary damage to patients, the technology provides a new technical platform and means for clinical detection of liver cancer, and has a strong practical application value.

The application discloses a recombinant escherichia coli for producing N-acetylneuraminic acid as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. The recombinant escherichia coli can grow in glucose and glycerol double carbon sources, synthesize N-acetylneuraminic acid and has extremely low acetic acid generation by knocking out 6-phosphofructokinase, introducing a glycerol kinase mutant, replacing PTS phosphotransferase I with a glucose-promoted diffusion transporter and optimizing a promoter. On this basis, the application further knocks out the 6-phosphofructokinase coding gene pfkB, introduces a heterologous ED pathway from Pseudomonas aeruginosa, and further improves the yield under the hole plate level to 9.44 g / L through copy number optimization and RBS intensity optimization.